Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Rhea-AI Summary

Longboard Pharmaceuticals (NASDAQ: LBPH) announced the presentation of LP352, a selective 5-HT2C receptor superagonist, at the 2022 AES Annual Meeting. The data includes the effects of LP352 on prolactin and its binding activity at 5-HT2 receptors. The company is also hosting a scientific exhibit on the ongoing Phase 1b/2a PACIFIC Study, aimed at treating rare seizure disorders. The leadership team will be present to discuss LP352's potential as a best-in-class therapy for various developmental and epileptic encephalopathies.

Positive

• Presentation of promising data for LP352 at AES Annual Meeting.
• Focus on LP352 as a potential best-in-class therapy for rare seizure disorders.

Negative

• None.

• Presenting data evaluating LP352 engagement of central 5-HT2C receptors via effects on prolactin, and assessing binding activity and functional agonism of LP352 at the 5-HT2 receptors
• Hosting scientific exhibit highlighting the ongoing Phase 1b/2a PACIFIC Study, and LP352, a novel, highly selective 5-HT2C superagonist in development for rare seizure disorders

LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (DEEs), in two poster sessions at the 2022 AES Annual Meeting. Longboard will also host a scientific exhibit with members of its leadership team to highlight details of the ongoing PACIFIC study, and to discuss LP352 as a potential best-in-class therapy for people living with rare seizure disorders.

“We are committed to improving the lives of people living with rare epilepsies, and are pleased to have a meaningful presence at AES this year. We look forward to presenting data highlighting the intrinsic characteristics of LP352, as well as hosting discussions around our ongoing PACIFIC study and future development plans. We believe that LP352 has the promise to be a best-in-class therapy for a broad range of DEEs, and make a difference in these devastating conditions,” stated Dr. Randall Kaye, Longboard’s Chief Medical Officer.

Presentation & Event Details:
Title: Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist
Poster number: 1.290
Date/Time: December 3, 2022, from 12:00-2:00pm ET

Title: Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist
Poster number: 2.260
Date/Time: December 4, 2022, from 12:00-2:00pm ET

Longboard Scientific Exhibit: A Novel 5-HT2C Superagonist for Treatment of Rare Seizure Disorders: LP352 and the PACIFIC Study
Date/Time: December 5, 2022, from 2:00-5:00pm ET
Location: Room 207 A&B, Music City Center, Nashville, TN

About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies (DEEs). LP352 is currently being evaluated in a Phase 1b/2a clinical trial, the PACIFIC Study, for the potential treatment of seizures associated with DEEs. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system diseases and disorders.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about LP352’s potential to be a best-in-class therapy, Longboard’s participation in the upcoming 2022 AES annual meeting, Longboard’s clinical and preclinical programs, its ability to develop and deliver therapies, and its focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005353/en/

Corporate Contact:

Megan E. Knight

Head of Investor Relations

IR@longboardpharma.com

619.592.9775

Source: Longboard Pharmaceuticals, Inc.

FAQ

What is LP352 and its significance in treating seizure disorders?

LP352 is a novel, highly selective 5-HT2C receptor superagonist in development for treating seizures associated with developmental and epileptic encephalopathies.

When and where will Longboard Pharmaceuticals present LP352 data?

Longboard Pharmaceuticals will present LP352 data at the AES Annual Meeting on December 3 and 4, 2022.

What is the PACIFIC Study related to Longboard Pharmaceuticals?

The PACIFIC Study is a Phase 1b/2a clinical trial evaluating LP352 for the treatment of seizures associated with developmental and epileptic encephalopathies.

What does the recent press release indicate about Longboard Pharmaceuticals' future?

The press release indicates a commitment to advancing LP352 and highlights its potential as an effective therapy for rare seizure disorders.

What are the event details for the Longboard scientific exhibit?

The scientific exhibit will take place on December 5, 2022, from 2:00-5:00 PM ET at the Music City Center in Nashville, TN.